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Thyroidhormones(TH,includingtheprohormonethyroxine(T4)anditsactivedeiodinated derivative3,3,5-triiodo-L-thyronine
(T3)) are important regulators of vertebrates neurodevelopment. Speciﬁc transporters and deiodinases are required to ensure T3
access to the developing brain. T3 activates a number of diﬀerentiation processes in neuronal and glial cell types by binding to
nuclearreceptors, actingdirectlyontranscription.OnlyfewT3targetgenesarecurrentlyknown.Deeper investigationsareurgently
needed, considering that some chemicals present in food are believed to interfere with T3 signaling with putative neurotoxic
consequences.
1.What IstheLevelofTHintheBrain?
Congenital hypothyroidism causes mental retardation and
has irreversible consequences if not treated soon after birth
[1]. Routine testing of newborns allows a rapid diagnostic
and permits to initiate a therapeutic intervention, TH
supplementation, which usually restores most cognitive
functions. However, iodine deﬁciency is still considered to
be one of the most frequent causes of preventable mental
retardation in children worldwide [2, 3], prompting to rein-
force salt iodization in all countries [4]. Upon thyrotropin
(TSH) stimulation, thyroid gland mainly secretes T4, which
is deiodinated to produce T3. It is usual to assume that
measuring TSH, T4, and T3 levels in blood is suﬃcient to
estimate T3 level in brain. This is, however, ignoring that
T3 access in brain is highly regulated. Furthermore, even
after the onset of the fetal thyroid gland function, which
occurs only at midgestation in humans, fetal brain relies
on maternal TH. TH ﬁrst cross the placenta [5]a n dt h e n
the brain-blood barrier. This transport is thought to favor
T4 at the expense of T3 [6]. The predominant function of
transport across the brain-blood barrier has been shown by
using pregnant female rats, depleted of both maternal and
fetal T4 and T3 [6, 7]. In these conditions, administration
of excess of T4 during the second half of gestation increases
T4 and T3 levels in the maternal serum, and restores the T3
level in both fetal liver and fetal cortex. By contrast, maternal
administration ofT3leadstoa similar increase inT3levelfor
the fetal liver, implying its transport through the placenta,
but to partial restoration of T3 level in fetal cortex. This
conﬁrms the importance of diﬀerential T4 and T3 transport,
and outlines the requirement of local conversion of T4 by
deiodination, performed by type 2 deiodinase (D2), which
is already present in glial cells at fetal stage. It has been
calculated that, in physiological situation, 80% of T3 in
rodent brain might be produced by local deiodination of T4.
The diﬀerential transport of T4 and T3 has an important
consequence: maternal hypothyroxinemia, that is, low T4
level in maternal serum with T3 and TSH levels within
normal range, is a cause of neurodevelopmental disorders
[3]. Even mild maternal hypothyroxinemia was recently
found to be associated with a higher risk of delay in the onset
of expressive language of children [8]. This situation is much
more frequent than overt hypothyroidism in geographical
areas with low iodine uptake. Reporter mice have been
made, in which lacZ expression is controlled by a Gal4-TRα1
artiﬁcial fusion protein, to visualize T3 signaling in brain
[9]. These so-called FINDT3 mice revealed two interesting2 Journal of Thyroid Research
features. First T3 visibly activates transgene expression at
fetal stage (embryonic day 15.5). Second T3 signaling is
highly heterogeneous, and large variations of reporter gene
expression are observed depending on brain areas. Midbrain
and telencephalon appear to be places of high signaling. This
signaling patternin adultsiswell correlatedwith T3distribu-
tionmeasured in various brain areas [10, 11], suggesting that
local T3 concentration is the main determinant of signaling
and that unknown mechanisms maintain an heterogeneous
distribution of T3 in brain. A number of transporters have
been identiﬁed, which might participate to the transfer of
TH to the brain [12]. However, knockout of individual
transporters does not seem to aﬀect neurodevelopment,
suggesting a cooperation between several transporters. One
transporter that received considerableattentionisthe mono-
carboxylate transporter 8, encoded by an X-linked MCT8
(SLC16A2)gene.Human mutationsofMCT8 increase rather
than suppress TH circulating levels but have dramatic
consequences on neurodevelopment, therefore suggesting a
predominant function of MCT8 for TH transport across
the brain-blood barrier [13]. However, the knockout of
MCT8 does not have any obvious inﬂuence on mouse brain
developmentandthereasonsforthisdiscrepancyareunclear.
Two alternative possibilities can be proposed: the ﬁrst would
be that human MCT8 is able to transport not only TH
but also some unknown signaling molecule required for
properbraindevelopment.This hypothesisisconsistentwith
the clinical observations of patients with MCT8 mutations,
which display a syndrome that is apparently distinct and
more severe that congenital hypothyroidism. The other
possible explanation for the mild consequences of MCT8
mutation in mice could be that other transporters, for
example, the OATP14, LAT1, and LAT2 transporters, are
present at earlier stages in the rodent brain, and can
compensate for MCT8 deﬁciency in this species [14–16].
Knocking-out the Dio2 gene, which encodes D2, allowed
to precisely address the function of T4 deiodination during
fetal brain development, but led to surprisingly mild pheno-
typic alterations. No major change in T3 level was observed
in serum. The reduction of T3 level at postnatal day 15
(P15) was only 50% in cerebellum and hypothalamus, and
not signiﬁcant in cortex [17, 18]. T3 level was normalized
in adult brain [19]. Gene expression analysis and neurobe-
havior testing conﬁrmed a very mild neurodevelopmental
phenotype [17]. Crossing with FINDT3 reporter mice
indicated that the spatial pattern of TH signaling was not
obviously aﬀected throughout development (L. Quignodon
unpublished data). Type 1 deiodinase (D1 encoded by Dio1)
is the other enzyme able to convert T4 into T3, and is mainly
expressed in liver. Surprisingly, elimination of both Dio1
and Dio2 did not aggravate the neurobehavioral phenotype.
Although Dio1/Dio2 combined knockout increased T4 level,
T3 level was maintained in serum [18] and adult brain [19].
Dio2 knockout was also combined to MCT8 knockout [19,
20]. For a set of genes that are positively regulated by T3 in
cortex, this combination resulted in decreased expression, in
both juveniles and adults. This suggests that T3 is produced
bylocaldeiodinationofT4,ordirectlytransportedbyMCT8,
and that blocking both pathways leads to a status close to
hypothyroidism in cortex. Looking at genes that are found
to be upregulated in hypothyroid cortex revealed, however,
that the situation is more complex, as, for these negatively
regulated genes, only Dio2 knockout had a inﬂuence on
expression level. Since the molecular mechanism underlying
negative regulation of gene expression by T3 is unknown,
this observation is diﬃcult to explain, but probably suggests
that the entry route of T3 in brain is somehow an important
information to deﬁne individual gene regulation status.
The third known deiodinase, type 3 deiodinase (D3,
encoded by Dio3), is responsible for T3 catabolism and is
expressed inseveralbrainareas [21].AsDio3gene expression
in brain is upregulated in case of hyperthyroidism, local T3
catabolismcanactasasafetypathwaytoprotectbrainagainst
excess of T3. Dio3 knockout mice were crossed to FINDT3
reporter mice [22]. This revealed a slow accumulation of T3
in the anterior cortex, indicating that catabolism is required
to regulate T3 level in adult cortex. Dio3 knockout did not
eliminate the spatial heterogeneity of T3 signaling, at early
and late stages, ruling out a major function of D3 in deﬁning
the spatial distribution of T3 in brain. In adult hypothala-
mus, local control of T3 level by deiodinases appears to be
used to sense and react rapidly to external signals. Local TH
metabolism participate to hypothalamic response to feeding
status [23], inﬂammation [24], seasonal change [25, 26],
and TRH feedback regulation [27]. This example might
prompt to reexamine the possibility that rapid metabolism
could also inﬂuence local environment during development.
In conclusion, T3 signaling level greatly varies in brain,
depending on brain areas, cell type, and developmentalstage
and measuring TH levels in blood is poorly informative.
Although the system generating this heterogeneity is not
understood, it appears as a very robust and insensitive to
genetic mutation aﬀecting TH transport and metabolism.
2.NuclearReceptorsFunction
inNeurodevelopment
The THRA and THRB genes encode a number of isoforms
[28, 29]. Among these only TRα1, TRβ1, and TRβ2a r e
considered as T3-dependent activators of nuclear transcrip-
tion. TRα1 mRNA is ubiquitous in brain, both in neuronal
and glial cell types whereas TRβ1 expression is more
restricted with prominent expression in zones of neuroblasts
proliferation such as the germinal trigone and the cortical
ventricular zone. TRβ2 expression in brain is limited to the
developing hippocampus and striatum [30–32]. To more
precisely address THRA expression pattern, a mouse strain
that expresses TRα1 and green ﬂuorescent protein (Gfp) as
ac h i m e r i cp r o t e i nf r o mt h eTHRA locus has been recently
created by homologous recombination [33]. Immunocyto-
chemistry against Gfpconﬁrmedabroadexpression,butalso
indicates important variations in expression level. Although
very reliable, this method is probably of limited sensitivity,
and absence of detection should not be taken as a proof for
absence of expression. For example, Gfp is detected ﬁrst at
embryonic day 13.5 (E13.5) whereas in situ hybridization
indicates earlier expression [30]. One interesting case is the
Purkinje neurons in cerebellum, in which TRα1 expressionJournal of Thyroid Research 3
decreases overtime while TRβ1 gradually increases, suggest-
ing a series of postnatal maturation events [34] enrolling the
two receptors sequentially.
Due to the diﬃculty to detect endogenous proteins by
Western blotting [35] or immunocytochemistry [36], THRA
and THRB expression studies in brain have been limited
to mRNA analysis. This is regrettable because TRα1m R N A
can encode several proteins, beside the canonical receptor
[37]. Among these, the p43 protein is translated from a
downstream AUG codon,providing a 43kDa proteinlacking
theN-terminusoftheTRα1 canonicalreceptor.Thisp43iso-
form has been proposed to be targeted to mitochondria and
to regulate mitochondrial genome transcription, providing a
possible complement to the well-known nuclear activation
of genes encoding mitochondrial enzymes [38]w h i c hi s
relevant to neurodevelopment [39, 40]. The involvement
in neurodevelopment of p43, as well as other so-called
nongenomic pathways for T3 action [41] would merit
speciﬁc investigation. T3 is also a precursorofthyronamines,
which are present in brain, and activate a diﬀerent class of
membranes receptors also expressed inbrain [42], butwhich
neurodevelopmental function has not yet been evaluated.
Initial studies of THRA and THRB knockouts were
surprising. THRA knockout has no visible consequence
on cerebellum, a posterior brain structure which postnatal
development is highly sensitive to TH deﬁciency, and is
the most classical model to study congenital hypothy-
roidism in rodents [43]. It induces increased anxiety in
adults, which probably involves hippocampus function, but
does not necessarily reﬂect a developmental defect. THRB
knockout aﬀects hearing [44]a n dv i s i o n[ 45]b u tn o t
the central nervous system development. No developmen-
tal defect has been reported after combining THRA and
THRB knockout [46, 47]. The inability of THRA/THRB
knockout to phenocopy congenital hypothyroidism was
explained by depleting THRA knockout newborns of T3 by
potassium perchlorate and 1-methyl-2-mercaptoimidazole
treatment. In the cerebellum of these mice, the persistence
of the external granular layer, a typical sign of congenital
hypothyroidism normally induced by T3 depletion, was
absent [48]. This strongly suggests that the manifestations
of congenital hypothyroidism in brain are mainly due
t ot h ep r e s e n c eo fu n l i g a n d e dT R α1, which is bound to
DNA and represses transcription. Knockin mutations in
THRA have been produced to introduce point mutations
in the TRα1 reading frame and compromise its ability
to transactivate upon T3 binding, without impairing its
ability to repress transcription. As expected, such mutations,
unlike the THRA knockout, lead to a cerebellum phenotype
resembling congenital hypothyroidism [49, 50], and these
defectsare notlimited to cerebellum[51, 52]. WhetherTRα1
istheonlyactiveT3receptorduringcerebellumdevelopment
remainsunclear.OneTHRBknockinmutationalsoproduces
a cerebellum phenotype resembling hypothyroidism, with
some important diﬀerences, perhaps due to the associated
increase in circulating TH levels [53, 54]. When given to
hypothyroid pups, TRβ selective ligands seem to have an
eﬀect limited to Purkinje neurons [48, 55]. However, the
action of T3 on in vitro Purkinje cells dendritogenesis
appears to be depending on TRα1 rather that TRβ1[ 56].
Finally,manyhumangermlinemutationshavebeenreported
in the human THRB, but not THRA, gene, responsible
for a syndrome of resistance to TH [57]. Although these
mutationscanbeacauseofIQdeﬁcit,theydonothavemajor
neurological consequences [58].
3.THand Neurodevelopment:
HowMuchIsCell Autonomous?
Most detailed studies are focused on cerebellum postnatal
development in rodents, where each cell type is sensitive in
some respect to TH deﬁciency: the inward migration of the
granular cell precursors (GCPs) present in the granular layer
cells (EGL) is inhibited, the development of the dendritic
arborization of Purkinje neurons is impaired, and the
maturation of the GABAergic interneurons is delayed [59].
The proliferation and diﬀerentiation of glial cells, including
astrocytes [60, 61], oligodendrocyte precursors [62], and
microglia [63]a r ea ﬀected. The morphology of Bergmann
glia, a speciﬁc type of radial glia found only in cerebellum,
is abnormal [64]. The diversity of these eﬀects raises several
possibilities for the mode of action of T3. The ﬁrst would
be that the repertoire of T3 target genes is completely
diﬀerent in diﬀerent cell types, and that genetic programs
governing cell migration, cell proliferation, and cytological
maturation are regulated in a cell-speciﬁc manner. In this
case, the chromatin status in a given cell type would exert
a predominant inﬂuence to deﬁne the repertoire of TR target
genes. The alternative would be that T3 exerts similar eﬀects
in diﬀerent cell types, controlling a shared repertoire of TR
target genes, but that this cell-autonomous response would
represent only a small fraction of the observed eﬀects of
T3. TH deﬁciency is known to aﬀect the level of several
neurotrophic and growthfactors in brain, which are required
for proper development [65, 66]. Cell culture can be used to
distinguish between these two possibilities, and to address
the cell autonomous response of puriﬁed or enriched cell
populations to T3, isolated from their natural environment.
Purkinje cells [56], oligodendrocyte precursors [67], and
astrocytes [68] were all shown to respond to in vitro stimula-
tion by T3. By contrast, impaired migration of GCPs, which
is a main sign of congenital hypothyroidism, is possibly an
indirect eﬀect for several reasons. First, this cell type does
not express TRα1a tah i g hl e v e l[ 33]. Second, microarray
analysis, performed on primary cultures of GCPs, identiﬁed
very limited changes in gene expression after T3 exposure,
and failed to establish a direct link between T3 and known
mechanism of neuronal migration [69]. Third, according
to in situ hybridization, GCPs do not express THRB,b u t
their migration is aﬀected by the TRβ
￿337T mutation [54].
Finally, GCPs do not produce the T3-regulated neurotrophic
factors (neurotrophin 3, insulin-like growth factor-1, Sonic
hedgehog, and brain-derived neurotrophic factor) but need
these neurotrophic factors for their proliferation, inward
migration, and diﬀerentiation [70–72]. As Purkinje cells
are the main source of Sonic hedgehog and insulin-like
growth factor-1, they probably play a central role in a local
network of cellular interactions. However, if this local eﬀect4 Journal of Thyroid Research
is plausible,a more indirect, systemic, inﬂuence ofT3 cannot
be ruledout.Inthat respect, itis remarkable thatametabolic
disease, which is clearly restricted to the liver, has been
found to impact GCPs inward migration [73]. All these
observations suggest that GCPs migration, which is required
to give rise to more than 90% of the cerebellum neurons,
doesnot result from a cell autonomous actionofT3. Adirect
genetic demonstration of this hypothesis would be possible
using the CRE/loxP technology, for which THRA [50]a n d
THRB [44] alleles are available.
4.T3Target Genes
It is striking that genome-wide analysis performed by a
numberofgroupsovertheyears, using avariety ofprotocols,
identiﬁed only few direct T3 targets in neural cell types,
deﬁned as genes for which transcription is under the direct
control of TRα1o rT R β1 bound to neighboring regulatory
sequences. Microarray analysis showed that in vivo T3
treatment has a very limited eﬀect on transcriptome of
whole cerebellum [74–76], or fetal cortex [77], compared
to adult striatum [78] or other tissues [79]. Comparison
between these studies also suggests that T3 response is
very diﬀerent in diﬀerent brain areas and at diﬀerent
developmental stages [80]. The eﬀect of graded degrees
of TH deﬁciency, induced by propyl-thio-uracyl, on gene
expression has been studied in postnatal hippocampus and
cortex. Interestingly, transcriptome is aﬀected in a dose-
dependent manner, speciﬁc gene clusters being sensitive
to only mild hypothyroidism [81]. Whereas many putative
T3 target genes have been listed in these broad surveys,
most changes are not rapidly reversed when T3 is given to
hypothyroid animals, and might reﬂect changes in the cell
composition of the considered area, or in the diﬀerentiation
s t a t u so rt h ec e l lt y p e s .T h i si sp r o b a b l yt h ec a s e ,f o r
example, for genes expressed in mature oligodendrocytes,
as diﬀerentiation of this cell type is known to be regulated
by T3. The actual demonstration of direct regulation by
T3/TR requires deeper investigations, which have been done
in only few cases. First, transcriptional regulation in a
primary culture system, where environmental parameters
can be controlled, can be used to reinforce the hypothesis
for a direct regulation. Second, transient expression assays
can be used to test the ability of gene promoter regions
to confer T3 responsiveness to reporter plasmid constructs.
However, this approach is often of little physiological
relevance and is hardly feasible in appropriate cell types.
Finally, chromatin immunoprecipitation, now considered as
a gold standard, can demonstrate actual binding by TRα1
or TRβ1 on putative response elements in their natural
genomic environment. This method appears to be much
more reliable than in vitro protein/DNA interaction assays,
which do not account for the complexity of the cellular
chromatin context but remains technically challenging for
several reasons. First, data obtained in other systems suggest
that the distance between TR binding sites and transcription
start site can be very large, making it diﬃcult to make a
selection among many putative response elements, and to
ensure that TR occupancy is responsible for the observed
regulation. Second, it is hardly feasible to perform such
studies on puriﬁed cerebellar cell populations. Preparing
chromatin from whole cerebellum [82] mainly addresses
chromatin occupancyin granular neurons, which represent a
large majority of the cerebellum cells. One attempt has been
made to identify new T3 target genes by the so-called chip-
on-chip high-throughput analysis [75].
Ironically, Hairless (Hr), encoding a transcriptional core-
pressor of several nuclear receptors, continues to be the best-
characterized T3 target gene in neurons, ﬁfteen years after its
identiﬁcation as a T3 target gene in rat postnatal cerebellum
[83]. Its expression is rapidly induced in a number of neu-
ronal cell types, and TR occupancy in the promoter region
has been conﬁrmed by chromatin immunoprecipitation
[69]. Among other likely TRα1/TRβ1 direct target genes in
neurodevelopment, are genes encoding a Kr¨ uppel-like tran-
scription factor (Klf9) [84], a poorly studied synaptotagmin-
related gene (srg1) [85], A kinase (PRKA) anchor protein
1( A k a p 1 )[ 69], neurogranin (RC3/Nrgn) [86], and, in the
fetal cortex, Ca2+/calmodulin-dependent protein kinase IV
(Camk4) [77]. The paucity in well-characterized T3 target
genes in brain mainly stems from the high cellular hetero-
geneity of neural tissues, and the lack of suitable in vitro
systems. It remains a bottleneck for the analysis of the mech-
anisms underlying the neurodevelopmental function of T3.
5.A New Classof NeurotoxicThyroid
Hormone Disruptors?
The above considerations have signiﬁcant consequences for
a matter of growing public concern: a number of chemicals
found at low concentration in the water and food are
suspected to exert a chronic toxicity by interfering with
T3 signaling, and might thus be considered as putatively
neurotoxic[87].Themainsuspected compoundsareBisphe-
nol A [88] ﬂame retardants (tetra-bromo-bisphenol A [89],
polybrominated diphenyl ethers [90]) and the persistent
polychlorobiphenyls (PCBs) [91]. Acute exposure of rats
to these compounds can lower or raise the circulating
level of TH. Xenopus tadpole metamorphosis, which is
fully dependent on TH, provides a basis for an in vivo
assay recognized by the Organisation for Cooperation and
Development(OECD) to deﬁne TH disruptors. The recently
developed assay, based on transgenic xenopus tadpoles is a
promising alternative, as it is rapid, and might better address
TRα1f u n c t i o n[ 92]. In some cases, transactivation assays
performed in transfected cell lines, or primary cultures of
neural cells, conﬁrm a possible direct inﬂuence of chemicals
on T3 signaling [93]. Although some compounds, like
coplanar PCBs, display some structural similarities with T3,
they do not seem to ﬁt into the T3 binding pocket and
are thus unlikely to act as high-aﬃnity TRα1/TRβ1l i g a n d s .
Recent data suggests, however, noncompetitive binding to
TR, preventing interactions with DNA [94]. In most cases,
a systemic inﬂuence on T3 metabolism and transport can
account for most of the observed in vivo toxicity after acute
exposure. Few experiments address the possibility that TH
disruptors can interfere with the neurodevelopmental func-
tion of T3, although signiﬁcant eﬀects on gene expressionJournal of Thyroid Research 5
in brain have been reported after exposure to a high dose
of PCBs [95, 96]o rb i s p h e n o lA[ 97]. One could argue
thatthepowerful compensatorymechanisms, revealedbythe
knockout of genes encoding transporters and deiodinases,
would be suﬃcient to maintain a stable level of T3 in
brain in most cases. Chronic exposure to a low dose of
chemicals, acting on T3 transport and metabolism, would
thus be unlikely to have neurotoxic consequences, unless
other signaling pathways are involved. In fact, T3 level in
brain is maintained in case of mild TH deﬁciency [98], a
condition which already requires exposure to high doses of
TH disruptors. By contrast, the results of THRA knockin
mutations suggest that exposure to any chemical that would
act as a TRα1 antagonist would be expected to signiﬁcantly
impair neurodevelopment. If such a hypothetical chemical
was TRα1 selective, it would not change the circulating level
of TH in serum, as this regulation is mainly exerted by
TRβ1a n dT R β2. Therefore TRα1 antagonists would not be
necessarily recognized by most in vivo tests. Deﬁning the
neural cell types that respond in a cell autonomous manner
to T3 during neurodevelopment, and then identifying direct
TRα1 target genes in these cells, appears therefore as a
prerequisite to the deﬁnition of relevant endpointsfor future
toxicity assay development.
6.Conclusion
Recent advances in our understanding of the neurodevel-
opmental function of T3 heavily rely on mouse genetics. A
complex landscape in which T3 probably exerts a number of
diﬀerentfunctions indiﬀerentcell typeshasbeenuncovered.
Coordinating thenetwork ofinteractions, mediatedbydirect
contacts and exchanges of diﬀusible factors, T3 synchronizes
neuronal and glial cells diﬀerentiation to ensure the onset
of functional neuronal structures. Whereas the transport
and metabolism of T3 is a robust system, which enables to
maintain T3 level within physiological range in many situ-
ations, signal transduction in the developing brain mainly
relies on the TRα1 isoform. Single amino-acid substitutions
can have dramatic consequences on neurodevelopment and
phenocopy congenital hypothyroidism. This is probably the
reason why no THRA germline mutation has been reported,
andwhysinglenucleotidepolymorphisminthehumanlocus
are only found in noncoding sequences.
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